These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 8916313)

  • 1. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC; Lin SF; Yao M; Chen TY; Tsao CJ; Chen TP
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
    Leone G; Pagano L; Marra R; Di Pietro N; Storti S; Sica S; D'Onofrio G; Ganzina F
    Haematologica; 1989; 74(1):57-61. PubMed ID: 2498185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
    Hołowiecki J; Krzemień S; Rudzka E; Krawczyk M; Wojnar J; Hołowiecka B; Wacławik A; Wojciechowska M; Kachel L; Cedrych I
    Acta Haematol Pol; 1994; 25(3):221-30. PubMed ID: 7992594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.